Montrusco Bolton Investments Inc. Decreases Stock Position in IDEXX Laboratories, Inc. $IDXX

Key Points

• Montrusco Bolton Investments cut its stake in IDEXX by 23.8% in Q4, selling 55,350 shares and now holding 176,932 shares worth about $117.1 million, making IDEXX its 22nd largest position.
• Insiders have been net sellers: CEO Jonathan Jay Mazelsky sold 23,326 shares for roughly $15.34 million and insiders sold a total of 45,957 shares (~$29.86 million) in the past 90 days, leaving insider ownership at 0.79%.
• IDEXX beat Q4 estimates with $3.08 EPS and $1.09B revenue (+14.3% YoY), issued FY2026 EPS guidance of $14.29–$14.80, and carries a consensus "Moderate Buy" analyst rating with a $760 price target and a market cap of about $44.95 billion.

Montrusco Bolton Investments Inc. cut its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 23.8% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 176,932 shares of the company's stock after selling 55,350 shares during the quarter. IDEXX Laboratories comprises 1.5% of Montrusco Bolton Investments Inc.'s holdings, making the stock its 22nd largest position. Montrusco Bolton Investments Inc. owned 0.22% of IDEXX Laboratories worth $117,091,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in IDXX. Empowered Funds LLC raised its stake in IDEXX Laboratories by 6.6% in the first quarter. Empowered Funds LLC now owns 1,538 shares of the company's stock valued at $646,000 after buying an additional 95 shares during the last quarter. Sivia Capital Partners LLC purchased a new stake in IDEXX Laboratories in the second quarter valued at about $265,000. Jump Financial LLC increased its holdings in shares of IDEXX Laboratories by 1,006.4% in the second quarter. Jump Financial LLC now owns 5,532 shares of the company's stock valued at $2,967,000 after purchasing an additional 5,032 shares during the period. Cary Street Partners Financial LLC purchased a new position in shares of IDEXX Laboratories in the second quarter worth about $164,000. Finally, Sei Investments Co. raised its stake in shares of IDEXX Laboratories by 218.7% in the second quarter. Sei Investments Co. now owns 120,587 shares of the company's stock worth $64,678,000 after purchasing an additional 82,755 shares during the last quarter. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In related news, CEO Jonathan Jay Mazelsky sold 23,326 shares of IDEXX Laboratories stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $657.55, for a total transaction of $15,338,011.30. Following the transaction, the chief executive officer owned 83,606 shares in the company, valued at approximately $54,975,125.30. This trade represents a 21.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Sophie V. Vandebroek sold 1,464 shares of IDEXX Laboratories stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $628.62, for a total value of $920,299.68. Following the transaction, the director owned 648 shares in the company, valued at approximately $407,345.76. The trade was a 69.32% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 45,957 shares of company stock valued at $29,862,109 in the last 90 days. 0.79% of the stock is owned by insiders.

IDEXX Laboratories Stock Up 0.9%

Shares of IDXX opened at $565.93 on Friday. The company has a debt-to-equity ratio of 0.23, a quick ratio of 0.90 and a current ratio of 1.23. IDEXX Laboratories, Inc. has a one year low of $427.70 and a one year high of $769.98. The stock has a market capitalization of $44.95 billion, a price-to-earnings ratio of 43.30, a PEG ratio of 3.41 and a beta of 1.72. The stock has a 50 day moving average price of $594.81 and a 200 day moving average price of $652.81.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Monday, February 2nd. The company reported $3.08 EPS for the quarter, topping the consensus estimate of $2.93 by $0.15. IDEXX Laboratories had a return on equity of 69.78% and a net margin of 24.62%.The firm had revenue of $1.09 billion during the quarter, compared to analysts' expectations of $1.07 billion. During the same period in the previous year, the business earned $2.53 earnings per share. The firm's revenue for the quarter was up 14.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2026 guidance at 14.290-14.800 EPS. Equities research analysts forecast that IDEXX Laboratories, Inc. will post 14.54 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Piper Sandler reduced their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a "neutral" rating for the company in a research note on Monday, February 9th. Weiss Ratings lowered IDEXX Laboratories from a "buy (b-)" rating to a "hold (c+)" rating in a report on Thursday, January 29th. Barclays dropped their target price on IDEXX Laboratories from $850.00 to $800.00 and set an "overweight" rating on the stock in a report on Thursday, February 5th. Citigroup assumed coverage on IDEXX Laboratories in a research report on Wednesday, April 15th. They set a "neutral" rating and a $650.00 price target on the stock. Finally, UBS Group lowered their price target on IDEXX Laboratories from $750.00 to $730.00 and set a "neutral" rating on the stock in a research report on Tuesday, February 3rd. Seven equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, IDEXX Laboratories presently has an average rating of "Moderate Buy" and a consensus price target of $760.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.